Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer

Dong W. Kim, Charles Blanke, Huiyun Wu, Yu Shyr, Jordan Berlin, R. Daniel Beauchamp, Bapsi Chakravarthy

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: Preoperative paclitaxel-based chemoradiotherapy may improve the response rates and survival in patients with localized esophageal cancer. We evaluated paclitaxel-based induction chemoradiotherapy in patients with localized esophageal cancer to determine its feasibility, clinical response, pathologic response, and overall survival. Methods and Materials: Between 1995 and 1998, 50 patients were enrolled in this study. At study entry, patients were categorized as either resectable or unresectable according to evaluation by an experienced thoracic surgeon. All patients were treated with paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 on Day 1, 29 with radiotherapy to 3,000 cGy in 15 fractions. Resectable patients underwent esophagectomy 4 weeks later. Postoperatively, patients received two cycles of paclitaxel 175 mg/m2 on Day 1 and 5-fluorouracil 350 mg/m2 and leucovorin 300 mg on Days 1-3, given every 28 days. Patients who were deemed unsuitable for resection from the outset continued radiotherapy to a total dose of 6,000 cGy. Results: Of the 50 patients, all began neoadjuvant chemoradiotherapy, 40 patients underwent surgery, and 25 patients completed postoperative chemotherapy. A pathologic complete response was seen in 7 patients (17.5%). Patients with a pathologic response had a median survival of 32.4 months vs. 14.4 months for nonresponders (p

Original languageEnglish (US)
Pages (from-to)397-404
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume67
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Esophageal Neoplasms
radiation therapy
Radiotherapy
cancer
Paclitaxel
Chemoradiotherapy
TP protocol
surgeons
Esophagectomy
Survival
Leucovorin
chemotherapy
entry
surgery
Fluorouracil
Cisplatin
induction
Thorax
Survival Rate

Keywords

  • Concurrent chemoradiotherapy
  • Gastroesophageal cancer
  • Neoadjuvant
  • Trimodality therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. / Kim, Dong W.; Blanke, Charles; Wu, Huiyun; Shyr, Yu; Berlin, Jordan; Beauchamp, R. Daniel; Chakravarthy, Bapsi.

In: International Journal of Radiation Oncology Biology Physics, Vol. 67, No. 2, 01.02.2007, p. 397-404.

Research output: Contribution to journalArticle

Kim, Dong W. ; Blanke, Charles ; Wu, Huiyun ; Shyr, Yu ; Berlin, Jordan ; Beauchamp, R. Daniel ; Chakravarthy, Bapsi. / Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. In: International Journal of Radiation Oncology Biology Physics. 2007 ; Vol. 67, No. 2. pp. 397-404.
@article{7637d84a40594463994f97c4ce7b0e0b,
title = "Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer",
abstract = "Purpose: Preoperative paclitaxel-based chemoradiotherapy may improve the response rates and survival in patients with localized esophageal cancer. We evaluated paclitaxel-based induction chemoradiotherapy in patients with localized esophageal cancer to determine its feasibility, clinical response, pathologic response, and overall survival. Methods and Materials: Between 1995 and 1998, 50 patients were enrolled in this study. At study entry, patients were categorized as either resectable or unresectable according to evaluation by an experienced thoracic surgeon. All patients were treated with paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 on Day 1, 29 with radiotherapy to 3,000 cGy in 15 fractions. Resectable patients underwent esophagectomy 4 weeks later. Postoperatively, patients received two cycles of paclitaxel 175 mg/m2 on Day 1 and 5-fluorouracil 350 mg/m2 and leucovorin 300 mg on Days 1-3, given every 28 days. Patients who were deemed unsuitable for resection from the outset continued radiotherapy to a total dose of 6,000 cGy. Results: Of the 50 patients, all began neoadjuvant chemoradiotherapy, 40 patients underwent surgery, and 25 patients completed postoperative chemotherapy. A pathologic complete response was seen in 7 patients (17.5{\%}). Patients with a pathologic response had a median survival of 32.4 months vs. 14.4 months for nonresponders (p",
keywords = "Concurrent chemoradiotherapy, Gastroesophageal cancer, Neoadjuvant, Trimodality therapy",
author = "Kim, {Dong W.} and Charles Blanke and Huiyun Wu and Yu Shyr and Jordan Berlin and Beauchamp, {R. Daniel} and Bapsi Chakravarthy",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.ijrobp.2006.08.062",
language = "English (US)",
volume = "67",
pages = "397--404",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer

AU - Kim, Dong W.

AU - Blanke, Charles

AU - Wu, Huiyun

AU - Shyr, Yu

AU - Berlin, Jordan

AU - Beauchamp, R. Daniel

AU - Chakravarthy, Bapsi

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Purpose: Preoperative paclitaxel-based chemoradiotherapy may improve the response rates and survival in patients with localized esophageal cancer. We evaluated paclitaxel-based induction chemoradiotherapy in patients with localized esophageal cancer to determine its feasibility, clinical response, pathologic response, and overall survival. Methods and Materials: Between 1995 and 1998, 50 patients were enrolled in this study. At study entry, patients were categorized as either resectable or unresectable according to evaluation by an experienced thoracic surgeon. All patients were treated with paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 on Day 1, 29 with radiotherapy to 3,000 cGy in 15 fractions. Resectable patients underwent esophagectomy 4 weeks later. Postoperatively, patients received two cycles of paclitaxel 175 mg/m2 on Day 1 and 5-fluorouracil 350 mg/m2 and leucovorin 300 mg on Days 1-3, given every 28 days. Patients who were deemed unsuitable for resection from the outset continued radiotherapy to a total dose of 6,000 cGy. Results: Of the 50 patients, all began neoadjuvant chemoradiotherapy, 40 patients underwent surgery, and 25 patients completed postoperative chemotherapy. A pathologic complete response was seen in 7 patients (17.5%). Patients with a pathologic response had a median survival of 32.4 months vs. 14.4 months for nonresponders (p

AB - Purpose: Preoperative paclitaxel-based chemoradiotherapy may improve the response rates and survival in patients with localized esophageal cancer. We evaluated paclitaxel-based induction chemoradiotherapy in patients with localized esophageal cancer to determine its feasibility, clinical response, pathologic response, and overall survival. Methods and Materials: Between 1995 and 1998, 50 patients were enrolled in this study. At study entry, patients were categorized as either resectable or unresectable according to evaluation by an experienced thoracic surgeon. All patients were treated with paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 on Day 1, 29 with radiotherapy to 3,000 cGy in 15 fractions. Resectable patients underwent esophagectomy 4 weeks later. Postoperatively, patients received two cycles of paclitaxel 175 mg/m2 on Day 1 and 5-fluorouracil 350 mg/m2 and leucovorin 300 mg on Days 1-3, given every 28 days. Patients who were deemed unsuitable for resection from the outset continued radiotherapy to a total dose of 6,000 cGy. Results: Of the 50 patients, all began neoadjuvant chemoradiotherapy, 40 patients underwent surgery, and 25 patients completed postoperative chemotherapy. A pathologic complete response was seen in 7 patients (17.5%). Patients with a pathologic response had a median survival of 32.4 months vs. 14.4 months for nonresponders (p

KW - Concurrent chemoradiotherapy

KW - Gastroesophageal cancer

KW - Neoadjuvant

KW - Trimodality therapy

UR - http://www.scopus.com/inward/record.url?scp=33846206827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846206827&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.08.062

DO - 10.1016/j.ijrobp.2006.08.062

M3 - Article

C2 - 17097833

AN - SCOPUS:33846206827

VL - 67

SP - 397

EP - 404

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -